Perspective Therapeutics (CATX) Income from Continuing Operations (2010 - 2026)
Perspective Therapeutics (CATX) posted Income from Continuing Operations of 28925000.0 for Q1 2026, up 24.44% sequentially from 38283000.0 in Q4 2025, and down 59.13% YoY from 70772610.71 in Q1 2025.
Perspective Therapeutics (CATX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Income from Continuing Operations for 17 years, with the latest figure at 28925000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 59.13% year-over-year to 28925000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 115176000.0 (down 33.4% YoY) and the FY2025 annual result came in at 104428000.0, down 30.55% from the prior year.
- Income from Continuing Operations grew to 28925000.0 in Q1 2026 per CATX's latest filing, from 38283000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 371000.0 in Q1 2023 and troughed at 41828000.0 in Q4 2024.
- A 5-year average of 15919647.06 and a median of 11825000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 72.46% in 2023, then tumbled 3087.33% in 2024.
- Over 5 years, Income from Continuing Operations stood at 7335000.0 in 2022, then plunged by 148.98% to 18263000.0 in 2023, then tumbled by 129.03% to 41828000.0 in 2024, then climbed by 8.48% to 38283000.0 in 2025, then grew by 24.44% to 28925000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 28925000.0, 38283000.0, and 25969000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.20 Bn | 194.60 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 129.69 Bn | 126.21 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 120.14 Bn | 110.92 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.57 Bn | 32.62 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.09 Bn | 31.98 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.49 Bn | 23.17 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.19 Bn | 22.70 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Perspective Therapeutics | 387.89 Mn | 387.89 Mn | - | -26.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.98 Mn |
| Mar 31, 2026 | -28.93 Mn |
| Dec 31, 2025 | -38.28 Mn |
| Sep 30, 2025 | -25.97 Mn |
| Jun 30, 2025 | -22.00 Mn |
| Mar 31, 2025 | -18.18 Mn |
| Dec 31, 2024 | -41.83 Mn |
| Sep 30, 2024 | -15.12 Mn |
| Jun 30, 2024 | -11.21 Mn |
| Mar 31, 2024 | -11.83 Mn |
| Dec 31, 2023 | -18.26 Mn |
| Sep 30, 2023 | -9.57 Mn |
| Jun 30, 2023 | -9.49 Mn |
| Mar 31, 2023 | -371,000.00 |
| Dec 31, 2022 | -7.34 Mn |
| Sep 30, 2022 | -7.49 Mn |
| Jun 30, 2022 | -3.43 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Dec 31, 2021 | -1.60 Mn |
| Sep 30, 2021 | -2.59 Mn |